Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Schrage

Showing results (11-20 of 47) with videos related to

Pageof 5
Sort By:
Molecular Cancer|September 25, 2010
Kinome profiling of myxoid liposarcoma reveals NF-kappaB-pathway kinase activity and casein kinase II inhibition as a potential treatment optionStefan M Willems, Yvonne M Schrage, Inge H Briaire-de Bruijn, et al.
Melanoma Research|November 28, 2023
Real-world relapse-free survival data on adjuvant anti-PD-1 therapy for patients with newly diagnosed and recurrent stage III melanomaEmma H A Stahlie, Lisanne P Zijlker, Michel W J M Wouters, et al.
The American Journal of Pathology|January 31, 2009
Aberrant heparan sulfate proteoglycan localization, despite normal exostosin, in central chondrosarcomaYvonne M Schrage, Liesbeth Hameetman, Karoly Szuhai, et al.
The American Journal of Surgical Pathology|October 15, 2008
Assessment of interobserver variability and histologic parameters to improve reliability in classification and grading of central cartilaginous tumorsDaniël Eefting, Yvonne M Schrage, Maartje J A Geirnaerdt, et al.
Journal of Cellular and Molecular Medicine|July 16, 2008
Central chondrosarcoma progression is associated with pRb pathway alterations: CDK4 down-regulation and p16 overexpression inhibit cell growth in vitroYvonne M Schrage, Suzanne Lam, Aart G Jochemsen, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|May 30, 2026
Surgeon's treatment outcome prediction: accuracy and communicationLisa Vlug, Ellen C de Lange, Anouk A Kruiswijk, et al.
Histopathology|March 5, 2008
Myxoid tumours of soft tissue: the so-called myxoid extracellular matrix is heterogeneous in compositionS M Willems, Y M Schrage, J J Baelde, et al.
Journal of Surgical Oncology|August 13, 2020
The use of FDG-PET/CT to detect early recurrence after resection of high-risk stage III melanomaEmma H A Stahlie, Bernies van der Hiel, Marcel P M Stokkel, et al.
The Journal of the American Osteopathic Association|September 29, 2001
Adjunctive osteopathic manipulative treatment in women with depression: a pilot studyB J Plotkin, J J Rodos, R Kappler, et al.
European Journal of Cancer (Oxford, England : 1990)|December 17, 2009
COX-2 expression in chondrosarcoma: a role for celecoxib treatment?Y M Schrage, I Machado, D Meijer, et al.
Pageof 5

Showing results (11-20 of 47) with videos related to

Sort By:
Pageof 5
Molecular Cancer|September 25, 2010
Kinome profiling of myxoid liposarcoma reveals NF-kappaB-pathway kinase activity and casein kinase II inhibition as a potential treatment optionStefan M Willems, Yvonne M Schrage, Inge H Briaire-de Bruijn, et al.
Melanoma Research|November 28, 2023
Real-world relapse-free survival data on adjuvant anti-PD-1 therapy for patients with newly diagnosed and recurrent stage III melanomaEmma H A Stahlie, Lisanne P Zijlker, Michel W J M Wouters, et al.
The American Journal of Pathology|January 31, 2009
Aberrant heparan sulfate proteoglycan localization, despite normal exostosin, in central chondrosarcomaYvonne M Schrage, Liesbeth Hameetman, Karoly Szuhai, et al.
The American Journal of Surgical Pathology|October 15, 2008
Assessment of interobserver variability and histologic parameters to improve reliability in classification and grading of central cartilaginous tumorsDaniël Eefting, Yvonne M Schrage, Maartje J A Geirnaerdt, et al.
Journal of Cellular and Molecular Medicine|July 16, 2008
Central chondrosarcoma progression is associated with pRb pathway alterations: CDK4 down-regulation and p16 overexpression inhibit cell growth in vitroYvonne M Schrage, Suzanne Lam, Aart G Jochemsen, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|May 30, 2026
Surgeon's treatment outcome prediction: accuracy and communicationLisa Vlug, Ellen C de Lange, Anouk A Kruiswijk, et al.
Histopathology|March 5, 2008
Myxoid tumours of soft tissue: the so-called myxoid extracellular matrix is heterogeneous in compositionS M Willems, Y M Schrage, J J Baelde, et al.
Journal of Surgical Oncology|August 13, 2020
The use of FDG-PET/CT to detect early recurrence after resection of high-risk stage III melanomaEmma H A Stahlie, Bernies van der Hiel, Marcel P M Stokkel, et al.
The Journal of the American Osteopathic Association|September 29, 2001
Adjunctive osteopathic manipulative treatment in women with depression: a pilot studyB J Plotkin, J J Rodos, R Kappler, et al.
European Journal of Cancer (Oxford, England : 1990)|December 17, 2009
COX-2 expression in chondrosarcoma: a role for celecoxib treatment?Y M Schrage, I Machado, D Meijer, et al.
Pageof 5